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CLIV is a multiple antigen peptide ([PTKAKRRVVQREKR]4-K2-K-bA) that encompasses the cleavage region of the human
immunodeficiency virus type 1 (HIV-1) envelope precursor. It displays an antiviral activity against HIV-1 and HIV-2 and inhibits
HIV-1 Env-mediated cell-to-cell fusion. This effect has previously been attributed to interference with Env processing,
resulting in the expression of a nonfusogenic envelope [Virology (1998) 247, 137]. However, we show here that CLIV does not
alter the status of Env cleavage at steady state. Using various aggregation/syncytium assays that allow us to discriminate
between gp120/CD4 binding and binding followed by gp41-mediated fusion, we demonstrate that CLIV inhibits a step of the
cell-to-cell fusion process after CD4 binding. We demonstrate also that CLIV binds at 37°C to a single class of protein present
at the CD41 cell surface (Scatchard analysis: Kd 5 8 nM; Bmax 5 10
4 sites/cell) and that the fusion inhibition activity seems
to correlate with binding to this proteic component. In contrast, CLIV interacts with neither membrane-inserted nor
CD4-associated Env. We therefore propose that CLIV interferes after Env/CD4 binding with a step of the membrane fusion
process that may involve the C-terminal domain of gp120. © 2000 Academic Press
Key Words: HIV Env; processing; membrane fusion; anti-HIV peptide; cleavage sequence.
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The gp160 precursor of human immunodeficiency vi-
rus (HIV) type 1 (HIV-1) envelope (Env) is processed into
gp120 and gp41 by cellular subtilisin-like protein conver-
tases (Hallenberger et al., 1992; Decroly et al., 1994,
1996; Einfeld, 1996). This step takes place in a trans-
Golgi or post-Golgi compartment (Pfeiffer et al., 1997).
Mature cleaved Env is subsequently routed to the cell
surface, where the outer membrane gp120 subunit re-
mains noncovalently associated with the transmem-
brane gp41. The gp120 allows HIV attachment to target
cells, mainly through binding to the primary CD4 receptor
in a context of various coreceptors that, in addition to
chemokine receptors (Broder and Collman, 1997), in-
clude some already identified cell surface-associated
proteases (Kido et al., 1991; Avril et al., 1994). gp41
subsequently induces membrane fusion between HIV
and its target cell, leading to virus entry (Doms and
Peipert, 1997).
The gp160 cleavage occurs at the C-terminus (Ct) of
gp120 within a cleavage region (gp120//PTKAKRR1VVQ-
EKR2AVGIG//gp41 for HIVLai Env) presenting two highly
conserved endoproteolytic cleavage sites (named site1
and site2 in the text) composed of dibasic amino acid (aa)
1 To whom reprint requests should be addressed at Biochimie, Fac-
dlte´ de Me´decine, B Pierre Dramard, 13015 Marseille, France. Fax:
3-491-69-88-47. E-mail: fenouillet.e@jean-roche.univ-mrs.fr.
169equences (Kieny et al., 1988; McCune et al., 1989).
leavage at site2 is considered to be indispensable for
the production of fusogenic gp41 species because it
unmasks the hydrophobic AVGIG sequence, which con-
stitutes the gp41 N-terminal (Nt) fusion peptide. In con-
trast, cleavage at site1 produces a gp41 subunit present-
ing the polar aa sequence VVQREKR upstream from the
fusion peptide, which impairs its fusogenicity. Thus ac-
cording to current knowledge, the role of site2 is defined,
whereas that of site1 remains to be clarified. It must
be noted that site1 is highly conserved among HIV-1
(PTKAKRR) and HIV-2 (PT??KR is the consensus HIV-2
sequence; GenBank database, 1990) strains.
The primary observations that alteration of gp160
cleavage by mutations at site2 inhibits Env fusogenicity
nd, hence, HIV infection (Kieny et al., 1988; McCune et
l., 1989; Freed et al., 1989; Bosch et al., 1990; Dubay et
l., 1995) led us and others to design peptide compounds
o interfere with the enzymatic machinery involved in Env
rocessing and to block HIV infection at the virus–cell
usion step. Indeed, three independent groups have re-
orted the synthesis of peptides derived from the gp160
leavage region and active on both HIV spread in CD41
cell cultures and Env-mediated cell-to-cell fusion (Hal-
lenberger et al., 1992; Decroly et al., 1994; Sabatier et al.,
1996; Barbouche et al., 1998a). However, the mode of
action of these compounds remains unclear because
their strong anti-HIV activity is associated with a rather
weak effect on Env processing. In their presence, a
0042-6822/00 $35.00
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170 BARBOUCHE ET AL.substantial amount of cleaved Env is detected at the
surface of both virus- and Env-expressing cells. This
observation is not consistent with the hypothesis that the
inhibition of Env-mediated membrane fusion by these
peptide constructs is directly linked to intracellular Env
processing inhibition.
CLIV is one of these anti-HIV constructs. This multiple
antigen peptide (MAP; four branches of the PTKAKRRV-
VQREKR sequence) displays a potent anti-HIV activity in
vitro. It has been shown to block infection induced by
HIV-1 and HIV-2 infection in various CD41 and CD42 cell
lines and to inhibit HIV-1 Env-mediated cell-to-cell fusion
(Sabatier et al., 1996; Barbouche et al., 1998a). Based on
revious reports (Hallenberger et al., 1992; Decroly et al.,
994) and because Env processing is slightly delayed in
he presence of the MAP (Barbouche et al., 1998a), we
irst attributed the anti-HIV activity of CLIV to interference
ith Env processing and, hence, production of fusogenic
p41. However, the amount of cleaved Env at the cell
urface in the presence of CLIV appears to be sufficient
o mediate membrane fusion (Barbouche et al., 1998a),
nd this observation led us to question this mechanism.
RESULTS
LIV and Env processing
To document a potential effect of CLIV on gp160 pro-
essing and because furin is considered to be the pro-
otype of gp160 processing enzymes, we addressed the
bility of the peptide compound to inhibit furin activity in
n in vitro assay. Furin was purified from the supernatant
of cells infected with a furin-encoding VV vector, and its
activity was assessed using REKR-AMC fluorogenic pep-
tides. When used at concentrations superior or similar to
those that block both syncytium formation and HIV infec-
tion, none of the peptides derived from the gp120 Ct
domain altered furin activity (data not shown).
We have previously shown that in the presence of
CLIV, cleaved Env is associated with the cell surface, and
that gp120 is subsequently shed into the cell supernatant
(Barbouche et al., 1998a). Here, we undertook to further
investigate through Western blot analysis the cleavage
status of Env at steady state expressed in the presence
of CLIV.
As reported above, two potential cleavage sites have
been described in the Env sequence. The sequence of
CLIV encompasses cleavage site1 surrounded by 4 and
7 aa, whereas cleavage site2 is positioned at the extrem-
ity of the peptide. Thus we hypothesized first that the
undetectable effect of CLIV on the amount of cell-asso-
ciated cleaved Env at steady state (Barbouche et al.,
1998a) might be due to the fact that CLIV correctly mim-
ics only cleavage site1. Consequently, it could alter only
nefficient cleavage at site2, which may account for its
ow impact on Env cleavage under our Western blot
onditions. To address this hypothesis, we investigated ahe effect of CLIV on the cleavage of Env encoded by
VS1. The corresponding Env contains only the cleavage
ite1 sequence, and we considered that this situation
might facilitate the detection of an effect of CLIV on the
cleavage of Env. We did not detect any significant effect
of CLIV on the processing of VVS1-encoded Env (Fig. 1A).
Alternatively, CLIV could behave as a decoy that inter-
acts with the substrate binding site of the processing
2
FIG. 1. CLIV, Env processing, and CD4 binding. (A) CLIV and pro-
cessing at cleavage site1. Cells (106) were infected by VVS1 in the
resence (CLIV; 1025 M) or absence (C) of CLIV. Cell lysates were
nalyzed by SDS–PAGE (10%). After blotting, Env was detected with
uman anti-HIV antibodies (h) and peroxidase-coupled anti-antibodies
Abs) (Pr, precursor; TMP, transmembrane glycoprotein). (B) CLIV and
cleavage at site1/cleavage at site2” ratio. Cells (106) were infected by
VVEnv in the presence (CLIV; 1025 M) or absence (C) of CLIV. Cell
lysates were analyzed by SDS–PAGE (10%). After blotting, Env was
detected with either D7323 (anti-gp41 Ct) or D7324 (anti-gp120 Ct) and
with anti-antibodies coupled to peroxidase. (C) CLIV and Env/CD4
binding. Two days postinfection, cells (1–4 3 106) expressing recom-
binant Env at their surface were incubated with 125I-CD4 (3 3 105 cpm;
30 mCi/mg) in the presence (CLIV; 1025 M) or absence (C) of CLIV. As
ontrols, binding to uninfected cells (Uninf.) and binding to Env-ex-
ressing cells preincubated with cold soluble CD4 (1CD4; 1 mg/assay)
are indicated. After washing, cell-associated radioactivity was mea-
sured (n 5 2).enzyme in charge of cleavage at site . The presence of
n uncleavable Ct sequence represented on CLIV by the
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171C-TERMINUS OF HIV gp120 AND FUSIONpolylysine core could then block the catalytic activity of
the convertase. According to this hypothesis, an expla-
nation for the anti-HIV activity of CLIV might thus be that
cleavage at site2 is impaired while cleavage at site1,
generated by another protease, is retained. This effect
would result in the production of a nonfusogenic gp41
subunit presenting the polar VVQREKR sequence up-
stream from the fusion peptide. We addressed this point
in the context of native gp160 through the study of the
ratio of site1/site2 cleaved products by using D7324,
hich binds gp41 species presenting the VVQREKR Nt
equence (Fenouillet et al., 1992, 1993). This reagent
llowed us to use Western blot analysis to semiquantify
he gp41 species presenting the Ct of gp120 upstream
rom the fusion peptide, as reported by Fenouillet et al.
1992, 1993). The presence of CLIV was found not to
ncrease the amount of gp41 species containing the
VQREKR sequence (Fig. 1B).
Altogether, these results support the notion that CLIV
ntiviral activity cannot be explained by interference with
he intracellular processing of gp160.
LIV alters the fusion process at a post-CD4
inding step
We then investigated whether the potent and specific
ctivity of CLIV in vitro might be related to a still unknown
roperty of the corresponding Ct domain of the gp120
ubunit. We first assessed whether the presence of the
eptide during Env synthesis was sufficient to exert an
nti-HIV activity. This would be in agreement with an
ffect of CLIV on the biosynthetic pathway of Env. Ac-
ordingly, we performed three different syncytium forma-
ion assays in which CLIV was present during Env syn-
hesis and/or during the coculture of Env-expressing
ells and fusion partners.
First, Env was expressed using VVEnv at the surface of
ither CEM or BHK-21 cells. Lymphoid CD41 cells that
ere then added as fusion partners to allow the interac-
ion of surface-associated Env with membrane CD4 pre-
ented in a context of various coreceptors. Such assay
ormat is commonly used to specifically address Env-
nd CD4-mediated fusion (Ashorn et al., 1993) in the
bsence of other HIV proteins. It also allows us to effi-
iently and reliably discriminate between the Env/CD4
inding reaction and the membrane fusion step (Kieny et
l., 1988; Fenouillet et al., 1993; Ashorn et al., 1993): in
oth cell systems, native Env, expressed at the surface of
HK-21 or CEM cells by an rVV, interacts with CD4
resent at the surface of adjacent CD41 cells. This leads
to the formation of large aggregates (30–300 cells). The
presence of these aggregates depends on the expres-
sion on cells of surface-associated gp120. The relevance
of these aggregates in terms of gp120/CD4 interaction is
demonstrated by the fact that these formations do not
appear (1) when Env expression is achieved using an
a
nrVV encoding a soluble form of Env that does not asso-
ciate with cell surface (soluble gp120 and soluble gp160,
encoded by VVTG1132 and VVTG1163, respectively;
Kieny et al., 1988) or (2) when soluble CD4 (1 mg/100 ml)
s added into the culture medium. When cell surface
xpression of Env is achieved using an HIV Env-encod-
ng rVV-expressing native fusogenic Env (VVEnv, i.e.,
VTG9–1; Kieny et al., 1988), aggregates between Env-
nd CD4-expressing cells developed subsequently into
iant multinucleated cells (syncytia). These syncytia re-
lect specifically gp41-induced membrane fusion, as
emonstrated by the following data: large aggregates,
ut no syncytium, appear when Env is expressed at the
ell surface by a gene encoding a nonfusogenic enve-
ope resulting from (1) elimination of both cleavage site1
and site2 (VVTG1139; see Kieny et al., 1988), (2) mutation
f cleavage site2, which is essential for unmasking the
p41 fusion peptide (VVS1, i.e., VVTG1134; Kieny et al.,
988), and (3) deletion of the gp41 fusion peptide
VVTG1136; Kieny et al., 1988). These controls have been
erformed during the development of the syncytium as-
ays to determine the routine experimental procedures
nd to assess the reliability of the test format. Moreover,
n each experiment, the following controls were per-
ormed (not shown): (1) cell aggregation was inhibited
ore than 80% by the addition of soluble CD4 (1 mg/well);
2) infection by VVTG1163, which encodes for soluble
p160, did not induce aggregates or syncytium forma-
ion; and (3) infection with VV0, a VV vector coding for an
nvelope that binds CD4 but does not trigger membrane
usion, induced aggregation but not syncytium formation
Fenouillet et al., 1993).
Table 1 presents data obtained when Env was ex-
ressed at the CEM cell surface and when fusion part-
ers cells were MolT4 cells. The presence of CLIV during
he sole biosynthesis of Env in CEM cells was not suffi-
ient to achieve the potent inhibition of syncytium forma-
ion noted when the peptide was also present during the
oincubation step. This result supports our observation
hat a sufficient amount of cleaved Env is expressed at
he cell surface when synthesis occurs in the presence
f CLIV. This also is consistent with the fact that Env can
ediate fusion as soon as the peptide is removed from
he incubation medium. On the contrary, the addition of
LIV during the sole coculture of Env- and CD4-express-
ng cells significantly inhibited cell-to-cell fusion. These
esults demonstrate that to induce a strong antifuso-
enic activity, the peptide must be present during the
ontact period between Env-expressing cells and the
D41 fusion partner cells.
Importantly, although CLIV inhibited syncytium forma-
ion when present during the contact period between
usion partners and Env-expressing cells, cell aggrega-
ion remained unchanged. This indicates that the inter-
ction between Env and CD4 on adjacent cells occurred
ormally in the presence of CLIV.
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172 BARBOUCHE ET AL.Altogether, these observations demonstrate that CLIV
interferes with cell-to-cell fusion at a post-CD4 binding
step. This conclusion is supported first by results ob-
tained in a CD4 binding assay using labeled soluble
CD4: CLIV did not alter binding of 125I-CD4 to recombi-
nant Env expressed at the surface of VVEnv-infected
BHK-21 cells (Fig. 1C). Controls indicated that this bind-
ing was specific: (1) binding to uninfected BHK-21 cells
or to cells infected with VV1163 (data not shown; VV1163
encodes soluble gp160, which does not associate with
cell surface; Kieny et al., 1988) represented only about 5%
of the binding to Env-expressing cells; (2) binding was
inhibited 55–75% by preincubation of Env-expressing
cells with soluble CD4 (1 mg/assay) before the addition
f 125I-CD4 and 40–60% by preincubation of 125I-CD4 with
gp120 (1 mg/assay) (data not shown).
When Env was expressed at the surface of CD4-
BHK-21 cells, a significant inhibition (about 80%) of the
fusion between Env-expressing cells and CD41 MolT4
fusion partners was observed when CLIV was present
only during the coincubation step, whereas only a weak
inhibition was obtained when CLIV was present in the
culture medium solely during Env synthesis.
Last, when CEM cells chronically infected with HIVLai
were washed and further incubated with MolT4 cells
overnight in the presence of CLIV, a reduction in syncy-
tium formation by more than 70% was observed. As a
control, the addition of the anti-CD4-neutralizing Leu3a
antibody (500 ng/100 ml) in the incubation medium
locked cell-to-cell fusion.
These data demonstrate that CLIV specifically inhibits
he membrane fusion process in various systems at a
ost-CD4 binding step.
LIV binding to lymphocyte surface
The previous observation that CLIV binds cell surface
Barbouche et al., 1998a) led us to postulate that the
nhibitory effect of CLIV on cell-to-cell fusion may be
T
Aggregation and Fusion in
Condition Synthesis 1/contact 1 Synthesis 2/contact 1 Sy
Aggregates 111 1111
Syncytia 2 1
Note. CEM cells (2 3 105 cells/ml), cultured under conditions that
Methods), expressed at their surface Env in the presence (synthesis
partner cells (106 cells/ml) for 10 h in the presence (contact 1) or abs
ell aggregates or syncytia was assessed (1111 corresponds to 76–1
ll the experiment, that is, synthesis 2/contact 2; 111, 31–75%;
ggregation/fusion assay (1) soluble CD4 (1CD4) was added during the
xpressed either with VVTG1163, which produces soluble gp160, or w
nduce membrane fusion.elated to its ability to interact with the lymphocyte sur-
ace. We thus undertook to characterize this binding.When CEM cells were incubated with 125I-CLIV, maxi-
um binding was attained after 2 h. Binding was tem-
erature dependent, with a peak at 37°C (Fig. 2A). CLIV
lso bound specifically BHK-21 cells, albeit to a much
esser extent (Fig. 2B). Under these conditions, the pep-
ide was shown to bind the CEM cell surface in a dose-
ependent manner with a K0.5 value in the range of 20 nM
Fig. 2C). Saturation curves (Fig. 2D) were obtained by
ncubating cells with or without unlabeled CLIV and by
arying the concentrations of 125I-CLIV; Scatchard analy-
sis produced a linear curve from which the following
dissociation constant (Kd 5 8 nM) and receptor number
Bmax 5 10
4 sites/cell) were calculated. The shape of the
curve indicates a single class of binding affinity and
strongly suggests that CLIV binds a single component.
To assess the nature of this molecule, the protein coat of
the cell surface was removed by pronase. This treatment
abolished in a dose-dependent manner the subsequent
binding of CLIV, indicating that its ligand is a protein (Fig.
2E). In contrast, treatment with a high amount of hepari-
nase had no significant effect on CLIV binding, showing
that heparans were not involved in binding.
To assess further the specificity and relevance of CLIV
binding, we investigated the ability of two CLIV analogs
to inhibit CLIV binding (Fig. 2F). The inactive (Barbouche
et al., 1998a) CLV R.S analog did not efficiently compete
with CLIV binding, whereas the active anti-HIV (Bar-
bouche et al., 1998a) CLV L analog did.
We then explored the possibility that CLIV could bind
Env expressed after VVEnv infection at the surface of
either BHK-21 cells, which originally bind CLIV only
poorly, or CEM cells. CLIV was found to similarly bind
uninfected and infected cells (Fig. 2G), which expressed
about 0.5 mg (CEM) and 3 mg (BHK-21) surface gp120/106
cells (immunocytometric quantification). The incubation
of CEM cells with soluble gp120, to achieve CD4/gp120
binding and to mimic to some extent post-CD4 binding
sence or Absence of CLIV
1/contact 2 Synthesis 2/contact 2 1CD4 VV1163 VV0
11 1111 1/11 2 111
11 1111 1 2 2
allow syncytium formation after VVEnv infection (see Materials and
bsence (synthesis 2) of CLIV. They were then incubated with fusion
ontact 2) of CLIV. The surface occupied per field of vision (n 5 4) by
the surface obtained for each parameter when CLIV was absent during
6–30%; 1, 6–15%; and 2, 0–5%). To address the specificity of the
bation step to inhibit the CD4/gp120 binding reaction, and (2) Env was
, which codes for a membrane form of Env that binds CD4 but cannotABLE 1
the Pre
nthesis
1
1
do not
1) or a
ence (c
00% of
11, 1
coincuevents, did not increase CLIV binding to the CEM cell
surface (Fig. 2H).
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FIG. 2. CLIV binding to the cell surface. (A) Binding and temperature
mCi/mg) in the presence (1CLIV; 3 3 1025 M) or absence of unlabeled
.1% NaN3 to impair endocytosis. After washing, cell-associated radioa
EM or BHK-21 cells. Cells (2 3 106) were incubated similarly with 125I-C
2). (C) K0.5 determination. CEM cells were incubated with increasing a
ell-associated radioactivity was measured (n 5 5). (D) Scatchard an
ncreasing amounts of 125I-CLIV (0.6–10 pM/assay) in the presence or a
binding. Specific binding data are calculated (inset) and plotted for Scat
reatments. Cells were treated with increasing amounts of pronase (0
washing, the cells were incubated with 125I-CLIV for 2 h in the presenc
n 5 3). (F) Ability of various CLIV analogs to inhibit CLIV binding to t
nalogs (CLVL, active analog; CLVR.S, inactive analog), as indicated,
radioactivity was measured (n 5 5). (G) Binding to cell surface-express
xpressing Env at their surface (about 0.5 and 3 mg/106 cells, respe
unlabeled CLIV. Uninfected (NI) cells were similarly processed. After
membrane CD4-bound Env. 125I-CLIV was incubated, in the presence
ncubated with secreted gp120 (1500 or 375 ng/ml). C indicates sam
ell-associated radioactivity was measured (n 5 2).We previously reported that CLIV, a MAP derived from
he cleavage region of Env, displays potent anti-HIVctivity (Sabatier et al., 1996; Barbouche et al., 1998a). We
first attributed this effect to the potential ability of the
cells (2 3 106) were incubated with 125I-CLIV (3 3 105 cpm/200 ml; 50
or various times in various temperature conditions, in the presence of
as measured (one experiment is shown; n 5 3). (B) Binding to either
he presence (CLIV) or absence of unlabeled CLIV before washing (n 5
of CLIV and a fixed amount of 125I-CLIV (3 3105 cpm). After washing,
f the binding to lymphocyte surface. CEM cells were incubated with
of an excess of unlabeled peptide (3 3 1025 M) to determine specific
nalysis (one experiment is shown; n 5 3). (E) Pronase and heparinase
g/ml) or with heparinase (Hep; 3 U/100 ml) or mock-treated (C). After
IV) or absence of unlabeled CLIV. Bound radioactivity was measured
surface. CEM cells were incubated with increasing amounts of CLIV
ixed amount of 125I-CLIV (3 3 105 cpm). After washing, cell-associated
. 125I-CLIV was incubated with VVEnv-infected (I) CEM or BHK-21 cells
. Incubation was performed in the presence (1CLIV) or absence of
g, cell-associated radioactivity was measured (n 5 3). (H) Binding to
) or absence (T4/Env) of unlabeled CLIV, with CD41 cells previously
milarly processed but without incubation with gp120. After washing,. CEM
CLIV f
ctivity w
LIV in t
mounts
alysis o
bsence
chard a
.3–2 m
e (1CL
he cell
and a f
ing Env
ctively)
washin
(1CLIVpeptide to interfere with gp160 processing. However,
expression of cleaved Env at the cell surface did not
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174 BARBOUCHE ET AL.appear significantly decrease at steady state in the pres-
ence of CLIV (Barbouche et al., 1998a). In addition, our
fforts here to demonstrate an effect of CLIV either on
he processing enzyme furin or on the status of Env
leavage at steady state were unsuccessful. This led us
o conclude that in the presence of CLIV, processing still
ccurs essentially at cleavage site2, which is productive
or fusion, and that an amount of cleaved Env sufficient to
ediate membrane fusion (Fenouillet et al., 1993) was
ubsequently expressed at the cell surface. Moreover,
yncytium assays have shown that Env-mediated fusion
ccurred as soon as CLIV was removed from the incu-
ation medium. It remains, however, possible that in the
resence of CLIV, a delay in Env processing (Barbouche
t al., 1998a) results in the incorporation of both un-
leaved gp160 and cleaved envelope within the same
ligomers and that this interferes to some extent with
nv functional folding, as described for Newcastle dis-
ase virus fusion glycoprotein (Li et al., 1998).
We then investigated other potential modes of action
f the inhibitory peptide, considering that its study may
eveal unexpected aspects of the Env-mediated mem-
rane fusion process and of the Ct of the gp120 subunit.
urprisingly, we observed that the presence of CLIV
uring the sole interaction of Env-expressing cells and
D41 fusion partner cells was sufficient to interfere with
the gp41-mediated membrane fusion process, whereas
cell aggregation resulting from Env binding to membrane
CD4 remained unchanged. These data demonstrate that
CLIV alters a membrane fusion event subsequent to the
CD4 binding step. It must be noted that this phenomenon
is not restricted to HIVLai-infected cells in that CLIV also
inhibits infection of C8166 cells by HIVHx10 (Sabatier et al.,
1996) and HIVMN (Barbouche et al., 1998a), CEM cells by
HIVLai, and CD4
2 Daudi cells by LAV-2/B (Sabatier et al.,
1996).
Steinhauer (1999) recently reported a model in which
activation of the fusogenicity of influenza virus hemag-
glutinin results from the processing of the antigen at the
cell surface. He postulates that processing induces con-
formational changes within a proteic pocket that mask
the fusion sequences of hemagglutinin before cleavage.
Based on this model and on the strong conservation of
cleavage site1 among HIV-1 and HIV-2 strains, we hy-
pothesize that the function of the hydrophilic residues
encompassing the cleavage region of Env may be to
interact with, and mask, the hydrophobic Nt of gp41 after
its intracellular activation by cleavage at site2. Proteoly-
sis of gp120 at site1 or conformation changes subse-
uent to interaction of the Ct of gp120 with a cell surface
oreceptor may then trigger fusion. Besides the known
unction of cleavage at site2 in the generation of the
active fusogenic Nt extremity of gp41, this hypothesis
postulates a role for both site1 and the Ct of gp120 in theltimate step of activation of gp41 fusogenicity after CD4
binding.Our hypothesis is supported by a report from Dubay et
al. (1995), who observed, but did not discuss, that single
mutations within the site1 sequence (KRR.ERR or
RR.ERS) left unchanged the cleavage status of the
orresponding envelopes, whereas mutations within
ite2 blocked the intracellular processing of Env. In con-
trast, when the envelope genes containing a mutated
site1 sequence were cloned into an infectious molecular
clone of HIVHXB2, the infectivity in H9 cells of the modified
iruses was severely decreased. Our model is also sup-
orted by our previous observation that inhibitory pep-
ides must contain a native site1 sequence together with
the residues spanning the two cleavage sites (Bar-
bouche et al., 1998a) and by a report of Verrier et al.
(1997) showing that a monoclonal antibody directed
against the PTKAKRR (site1) sequence efficiently blocks
he Env–membrane fusion process mediated by both
non-syncytium-inducing” and “syncytium-inducing” HIV-1
trains.
CLIV-induced fusion inhibition may rely on its interac-
ion with a cell surface component involved in the fusion
rocess. It is of note that protease activities associated
ith target cells and required for Env–membrane fusion
ave already been described (Kido et al., 1991; Avril et al.,
994). Moreover, we recently showed that a MAP de-
ived from the apex of V3 inhibits HIV entry through its
pecific interaction with CXCR4 (Barbouche et al., 2000).
We present here data that support the hypothesis that
CLIV acts through interference with a surface protein.
Indeed, CLIV binds the lymphocyte surface with high
affinity and the number of ligand per cell is about 104,
hich correlates with the number of CD4 receptor mol-
cules present on lymphocytes (McDougall et al., 1986).
Nevertheless, because we have observed that CLIV
binds to some extent BHK-21 cells, which possess nei-
ther CD4 nor HIV coreceptors of the chemokine receptor
family (Clapham et al., 1991; Lavi et al., 1997), it is unlikely
that the ligand of CLIV is one of these molecules. In
addition, CLIV did not bind Env expressed at the cell
surface, even when Env was first bound to membrane
CD4. This indicates that CLIV does not exert its activity
through binding to Env and does not alter the conforma-
tion of the glycoprotein through interactions with the Nt
of gp120, despite a potential proximity between the Nt
and Ct regions of gp120 (Moore et al., 1994; Sugiura et
al., 1999). Although aa sequences recognized by furin
bind cell surface heparan sulfates (Klimstra et al., 1999),
CLIV does not appear to interfere with HIV infection
through alteration of the known heparan sulfate–HIV
interaction (Mondor et al., 1998). The CLIV ligand was
further found to be a protein, as indicated by its sensi-
tivity to pronase treatment, and binding likely required
plasticity of the CLIV ligand in that peptide binding was
maximum at 37°C. Binding was potently inhibited by the
active analog CLVL but not by its inactive CLVR.S coun-
terpart, which also argues in favor of the specificity of the
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175C-TERMINUS OF HIV gp120 AND FUSIONbinding of CLIV. Furthermore, the concentration of CLIV
required to saturate the cell surface receptor correlates
with that required to suppress cell-to-cell fusion. These
two latter observations strongly support the hypothesis
that CLIV binding capacity at the cell surface is related to
its anti-HIV activity.
In conclusion, our results, which are supported by
published observations (Dubay et al., 1995; Verrier et al.,
1997), highlight a potential role for cleavage site1 and the
equence spanning the two cleavage sites in the mem-
rane fusion process at a post-CD4 binding step.
MATERIALS AND METHODS
nv expression systems and MAPs
Recombinant vaccinia viruses (rVV). VVEnv (VVTG9–1;
Kieny et al., 1988) encodes the native HIVLai env gene and
allows the expression of fusogenic Env associated at the
surface of rVV-infected cells. VVS1 (VV1134; Kieny et al.,
1988) produces an envelope containing only cleavage
site1, the coding sequence for cleavage site2 being mod-
ified (REKR . NEHQ); the corresponding non fusogenic
Env is cleaved into gp120 and gp41 at site1 and expressed
at the cell surface where it can bind membrane CD4.
MAPs. The MAPs were synthesized by the solid phase
technique using Fmoc/t-butyl chemistry and purified to
omogeneity by C18 reverse phase medium-pressure
iquid chromatography, as described by Barbouche et al.
1998a). The purity of the peptides (.98%) was assessed
y mass spectrometry. Their sequences are as follows:
LV L (long), [KIEPLGVAPTKAKRRVVQREKR]4-K2-K-bA;
CLV R.S, [KIEPLGVAPTKAKRSVVQREKS] 4-K 2-K-bA;
CLIV, [PTKAKRRVVQREKR]4-K2-K-bA; and CLIV Y, [PTKAK-
RVVQREKR]4-K2-K-Y. CLIV Y (5 mg), an active analog,
was incubated with 125I-Na (300 mCi) in a 4 nM Iodogen-
oated tube for 30 min at 20°C (Fenouillet et al., 1997).
Labeled CLIV Y (specific radioactivity, 50 mCi/mg) was
purified by Sephadex G-25 chromatography (PD10; Phar-
macia, Uppsala, Sweden).
CLIV and furin activity
Secreted human furin was purified from the superna-
tant of GH4C1 cells infected with a furin-encoding rVV as
described by Jean et al. (1993), except that 50 mM Tris-
acetate, pH 7.5, was used for DEAE chromatography.
Furin activity was assessed at 37°C using the pentapep-
tide fluorogenic substrate pERTKR-AMC (Enzyme Biosys-
tems, CA; 200 mM) in 50 mM Tris-acetate buffer, pH 7, 1
mM CaCl2, supplemented with the various peptides (5 3
025 to 1027 M). The reaction was stopped with acetic
cid. Fluorescence of free AMC was measured in micro-
ells with a Millipore Cyto-Fluor 23000 fluorescence
easurement system (excitation wavelength, 370 nm;
mission, 460 nm).yncytium formation
Human lymphoid CEM cells were cultured on 12-well
lates in RPMI 1640 medium supplemented with 5% fetal
alf serum (FCS) and 1% Gln (2 3 105 cells/ml). They
ere infected by VVEnv (0.2 pfu/cell) in the presence or
bsence of CLIV (1025 M). Such low cell density does not
llow a significant syncytium formation at 2 days postin-
ection. Cell supernatants were removed at 36 h postin-
ection before syncytia appeared, and CD41 MolT4 cells
106 cells/ml final dilution) were added as fusion partners
in the presence or absence of CLIV (1025 M) for 10
additional hours. Aggregates and syncytia were counted
at 2 days postinfection.
CD42 BHK-21 cells were cultured on 12-well plates
oated with polylysine in Glasgow medium supple-
ented with 5% FCS, 1% Gln, and 5% tryptose phos-
hate) (3 3 105 cells/ml). They were infected by VVEnv (1
pfu/cell) in the presence or absence of CLIV. Two days
postinfection, cell supernatants were removed and cells
were washed. Fusion partner MolT4 cells were then
added in the cultures in the presence or absence of CLIV
for 20 additional hours. Syncytia resulting from the fusion
of MolT4 cells with Env-expressing BHK-21 cells were
then counted.
CEM cells (105) chronically infected by HIVLai were
washed and then incubated with MolT4 cells (3 3 105)
overnight in the presence or absence of CLIV. Syncytia
were counted.
Env expression
Western blot analysis. rVV-infected cells (0.5 pfu/cell)
were washed once in PBS at 2 days postinfection and
lysed in 60 mM Tris–HCl buffer, pH 7.2, 20 mM EDTA, 2%
SDS, and 5% b-mercaptoethanol. After centrifugation,
cleared lysates were analyzed by SDS–PAGE (10%). Gels
were then blotted onto a nitrocellulose filter. After block-
ing the filter using 5% casein, staining was performed for
1 h with a pool of human HIV1 sera (1:500) with sheep
olyclonal antibodies D7324 (Aalto, Dublin, Ireland; di-
ected against the Ct of gp120; 1:500) or D7323 (Aalto;
irected against the Ct of gp41; 1:300) (Fenouillet and
luckman, 1992). Incubations and washes were per-
ormed in PBS, 0.5% casein (PBSC), and 0.5% Tween 20.
eroxidase-labeled anti-antibodies (Dakopatts, Glostrup,
enmark; 1:1000) and the Super Signal detection sys-
em kit (Pierce, Rockford, IL) were used to detect Env
pecies.
Quantification of CD4 binding to membrane-associ-
ted Env. Hamster CD42 BHK-21 cells (1–4 3 106 cells)
nfected by VVEnv (0.5 pfu/cell) and expressing Env at
heir surface were washed at 2 days postinfection with
BS. They were then incubated for 2 h at 37°C with
125I-CD4 (3 3 105 cpm) in the presence or absence of
CLIV in PBSC, 0.1% NaN3. NaN3 is a metabolic poison
that blocks energy metabolism and consequently pre-
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176 BARBOUCHE ET AL.vents endocytosis. CD4 was labeled (30 mCi/mg) in a 4
M Iodogen-coated tube before purification by G-25
hromatography, as described by Fenouillet et al. (1997).
ninfected cells were similarly processed to determine
he background binding of CD4. To assess further the
pecificity of the CD4/gp120 binding reaction, inhibition
f labeled CD4 binding to membrane Env was performed
s follows: (1) soluble CD4 (1 mg/106 cells) was incu-
ated with VV Env-infected cells for 15 min before the
ddition of 125I-CD4 and (2) secreted soluble gp120 (1 mg)
as preincubated with 125I-CD4 before the addition to
nv-expressing cells. After three washes, cell-associ-
ted radioactivity was measured.
LIV binding to the cell surface
CEM cells (2 3 106) were incubated at 4°, 25°, or 37°C
or various times in 50% PBS–50% culture medium, 0.1%
aN3, with
125I-CLIV (3 3 105 cpm/200 ml) in the presence
or absence of unlabeled CLIV (3 3 1025 M). The pres-
ence of NaN3 was shown previously (Barbouche et al.,
998b, 2000) to block both fluid phase- and receptor-
ediated internalization, allowing us to monitor cell sur-
ace-associated 125I-CLIV. After 2 washes with PBS, 0.1%
aN3, cell-associated radioactivity was measured. Scat-
hard analysis was performed as described by Bar-
ouche et al. (2000): briefly, 0.6–10 pM/assay 125I-CLIV
was used, and specifically bound radioactivity was de-
fined as the difference between radioactivity bound in
the presence or absence of an excess of unlabeled
peptide (3 3 1025 M). For CLIV binding to surface-asso-
iated Env, binding was assessed on either BHK-21 or
EM cells expressing Env at 2 days post-VVEnv infec-
ion. Env expression and binding experiments were per-
ormed as described above. To address the putative
inding of CLIV to CD4-associated Env, CD41 cells were
incubated first with recombinant soluble gp120 (500 ng),
which binds the membrane CD4 receptor, as assessed
by immunocytometry (data not shown), and then with
125I-CLIV. Assays were then performed as described
bove. Competition binding experiments were performed
imilarly with various concentrations of unlabeled ana-
ogs (1025 to 10210 M) and a fixed amount of labeled CLIV.
In enzyme treatments, to determine the nature of the
membrane ligand of CLIV, cells were submitted, as de-
scribed by Barbouche et al. (1998b, 2000) to pronase
(Sigma Chemical Co., St. Louis, MO; 0.1–2 mg/ml PBS for
15 min) or Heparinase I (Sigma; 30 U/ml RPMI 1640, 5
mM CaCl2 for 1 h) at 37°C. After two washes in culture
medium, cells were incubated with 125I-CLIV as de-
cribed above. Nonspecific binding and cell-associated
adioactivity were then determined.
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